Gateways to clinical trials: April 2004

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 3, 2004, Pages 211-244

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ADEFOVIR; AP 12009; ARGININE; ATORVASTATIN; AVASIMIBE; BMS 188797; BOSENTAN; BOTULINUM TOXIN B; BRL 55730; CEP 1347; CINACALCET; CP 461; CPG 7909; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); D 003; DESLORATADINE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DN 101; DURAMYCIN; EKB 659; ENALAPRIL; EPLERENONE; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; GADOLINIUM TEXAPHYRIN; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GTI 2040; INSULIN; LAMIVUDINE; MDX 210; MEPOLIZUMAB; NATALIZUMAB; NITROPRUSSIDE SODIUM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMALIZUMAB; PACLITAXEL; PACLITAXEL TOCOSOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PRAMLINTIDE; PROVENGE; PX 12; QS 21; RAGAGLITAZAR; RECOMBINANT ERYTHROPOIETIN; SITAXSENTAN; TALAGLUMETAD; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANEMIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; HYPERTENSION; LIVER TOXICITY; PERIPHERAL EDEMA; PHOTOTOXICITY; QT PROLONGATION; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMATITIS;

CLINICAL TRIALS; HUMANS;

EID: 2442590962     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (192)

1. Gokal, R. Darbepoetin alfa maintains hemoglobin concentrations at reduced dose frequencies in patients receiving peritoneal dialysis. J Am Soc Nephrol 2003, 14: Abst SU-PO1066.
2. McDevitt, L.M., Somerville, T.K., Smith, L.D., Corbett, J.L., Shihab, F.S. Darbepoetin alfa in renal transplant recipients: Subgroup analysis of response to treatment. J Am Soc Nephrol 2003, 14: Abst SU-PO573.
3. Schwartzberg, L., Shiffman, R., Tomita, D., Stolshek, B., Rossi, G., Adamson, R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003, 25(11): 2781.
4. Vinh, T.-T., Lewis, B.H., Yao, B., Yim, J. Initial experience with darbepoetin alfa in patients with myelodysplastic syndrome (MDS). Proc Am Soc Clin Oncol 2003, 22: Abst 2464.
5. Ploetz, S.G., Darsow, U., Simon, H.U. et al. Efficacy of an interleukin-5 blocking monoclonal antibody on eosinophils in hypereosinophilic syndrome. 22nd Congr Eur Acad Allergol Clin Immunol (June 7, 2003, Paris) 2003: Abst 256.
6. Merkulov, E., Nikolaev, A., Churkina, E. Dietary L-arginine supplementation inhibited platelet aggregation in patients with coronary artery disease. J Hypertens 2003, 21 (Suppl. 4): Abst P3.194.
7. Lazar, H.L., Bokesch, P.M., Fitzgerald, C., Lenta, F.V. Soluble human complement receptor Type I (TP10) limits ischemic damage during coronary artery bypass surgery with cardiopulmonary bypass. Circulation 2003, 108 (17, Suppl. 4): Abst 2324.
8. Schindler, T.H., Prior, J.O., Inubushi, M. et al. Effects of ACAT inhibition by PET on hyperemic myocardial blood flow responses in patients without and with stenosed coronary artery segments: A double-blind, randomized multicenter trial. Circulation 2003, 108 (17, Suppl. 4): Abst 1867.
9. Schelbert, H.R., Hassan, A., Garner, J., Di Carli, M.F. Effects of ACAT inhibition by positron emission tomography measured myocardial blood flow: A double-blind, randomized, mutilcenter trial. J Am Coll Cardiol 2003, 41 (6, Suppl. A): 460A.
10. Sudano, I., Taddei, S., Versari, D., Salvetti, A. Effect of ET-A receptor antagonism on systemic sympathetic nervous activity in hypertensive patients. J Hypertens 2003, 21 (Suppl. 4): Abst P3.118.
11. Barst, R.J., Langleben, D., Frost, A.D. et al. Sitaxsentan improves exercise capacity, NYHA functional class and hemodynamics in traditional and expanded study populations in pulmonary arterial hypertension (PAH). Circulation 2003, 108 (17, Suppl. 4): Abst 51.
12. Kane, G.C., Stanson, A.W., Garovic, V.D. Gadolinium as a contrast agent for catheter based renal arteriography. J Am Soc Nephrol 2003, 14: Abst SA-PO986.
13. Colwell, C.W., Berkowitz, S.D., Comp, P.C. et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood 2003, 102 (11, Part 1): Abst 39.
14. Shoback, D.M., Bilezikian, J.P., Turner, S.A., McCary, L.C., Guo, M.D., Peacock, M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(12): 5644.
15. Epstein, M., Weinberger, M., Lewin, A., Qian, J., Krause, S. Eplerenone dose as a determinant of hyperkalemia: A comparison of 2 clinical trials. J Am Soc Nephrol 2003, 14: Abst SA-PO492.
16. Clement, S., Dandona, P., Still, J.G., Kosutic, G. Oral modified insulin (HIM2) in patients with type I diabetes mellitus: Results from a phase I/II clinical trial. Metab Clin Exp 2004, 53(1): 54.
17. Weyer, C., Gottlieb, A., Kim, D.D. et al. Pramlintide reduces post-prandial glucose excursions when added to regular insulin or insulin lispro in subjects with type I diabetes. A dose-timing study. Diabetes Care 2003, 26(11): 3074.
18. Hermansen, K., Ronnemaa, T., Petersen, A.H., Bellaire, S., Adamson, U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care 2004, 27(1): 162.
19. Skrumsager, B.K. et al. Ragaglitazar: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol 2003, 43(11): 1244.
20. Ehlers, M.R., Klaff, L.J., D'alessio, D.A. et al. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res 2003, 35(10): 611.
21. Rutgeerts, P., Colombel, J., Enns, R. et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). 11th United Eur Gastroenterol Week (Nov 1, 2003, Madrid) 2003: Abst OP-G-297.
22. Travis, S.P.L., Yap, L., Hawkey, C.J. et al. RDP58 - a novel and effective oral therapy for ulcerative colitis (UC): Results of parallel prospective, multicentre, placebo-controlled trials. 11th United Eur Gastroenterol Week (Nov 1, 2003, Madrid) 2003: Abst OP-G-21.
23. Ondo, W.G., Hunter, C., Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004, 62(1): 37.
24. Zeitlin, P.L., Boyle, M.P., Guggino, W.B., Molina, L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004, 125(1): 143.
25. Raal, F.J., Marais, A.D., Klepack, E., Lovalvo, J., McLain, R., Heinonen, T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003, 171(2): 273.
26. van Giersbergen, P., Popescu, G., Dingamanse, J. Pharmacokinetics and tolerability of bosentan in patients with mild liver impairment. Clin Pharmacol Ther 2003, 73(2): Abst PIII-80.
27. Perrillo, R. et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126(1): 81.
28. Peters, M.G. et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126(1): 91.
29. Schwarz, K.B., Mohan, P., Narkewicz, M. et al. The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst 215.
30. Homoncik, M., Sieghart, W., Jessner, W. et al. Effect of therapy with pegylated interferon-alpha on platelet activation and apoptosis in patients with chronic hepatitis C. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst T1218.
31. Banfield, C., Cutler, D., Shneyer, L. et al. Desloratadine suppresses histamine- and allergen-induced cutaneous wheal and flare responses in allergic subjects during 6 months' treatment. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 666.
32. Kim, K.T., Sussman, G.L., Hebert, J., Lumry, W.R., Lutsky, B., Gates, D. Effect of once-daily desloratadine in patients with perennial allergic rhinitis (PAR): A double-blind, placebo-controlled study. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 25.
33. Skoner, D.P., Gentile, D.A., Gungor, A. et al. The effects of desloratadine (DL) on the allergic inflammatory response of the nasal mucosa associated with seasonal allergic rhinitis (SAR): A nasal mucosal biopsy study (NMBX). J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 51.
34. Meltzer, E.O., Harris, A.G. Desloratadine 5 mg once daily significantly improves individual and total symptoms compared with placebo in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 61.
35. Nayak, A., Casale, T., Miller, S.D. et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003, 24(5): 323.
36. Borchard, U.H.J., Daly, A.F., Plenker, A. Desloratadine: Safety and tolerability data in clinical practice. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 17.
37. Staats, P.S., Yearwood, T., Charapata, S.G. et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. A randomized controlled trial. JAMA - J Am Med Assoc 2004, 291(1): 63.
38. Koon, H.B. et al. Imatinib mesylate in AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 2003, 22: Abst 782.
39. Smallwood, G.A., Davis, L., Martinez, E., Stieber, A.C., Heffron, T.G. Non-responders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation. Am J Transplant 2003, 3 (Suppl. 5): Abst 1433.
40. Woods, G.L., Isaacs, R.D., McCarroll, K.A., Friedland, I.R. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 2003, 51(11): 1526.
41. Kelley, M.S., Honaker, M.R., Egidi, M.F., Shokouh-Amiri, M.H., Christenson, A.L., Gaber, A.O. Efficacy of low-dose valganciclovir for the prevention of CMV after organ transplantation. Am J Transplant 2003, 3 (Suppl. 5): Abst 1394.
42. Zhang, X., Patel, I.H., Lalezari, J. et al. Assessment of metabolic inhibition potential of enfuvirtide using a 5-drug cocktail in HIV-1 infected patients. Clin Pharmacol Ther 2003, 73(2): Abst PIII-73.
43. Wood, R., Arasteh, K., Stellbrink, H.-J. et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type I-infected patients. Antimicrob Agents Chemother 2004, 48(1): 116.
44. Baillie, G.M., Birsner, J.H., Taber, D.J. et al. Drotrecogin alfa (activated) (Xigris) in abdominal organ transplant recipients with severe sepsis. Am J Transplant 2003, 3 (Suppl. 5): Abst 1399.
45. Castano, G., Mas, R., Fernandez, L. et al. Effects of D-003 on the lipid profile of patients with type II hypercholesterolaemia - A phase II clinical study. Clin Drug Invest 2003, 23(12): 789.
46. Sager, P.T., Melani, L., Lipka, L. et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003, 92(12): 1414.
47. Kawano, H. et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003, 88(7): 3190.
48. Hiroaki, K., Yoshida, T., Hirai, N., Motoyama, T. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. Circulation 2003, 108 (17, Suppl. 4): Abst 2564.
49. Goldstein, J.L., Eisen, G.M., Hanna, D.B., Burke, T. Upper gastrointestinal (UGI) tolerability of valdecoxib, a COX-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Dig Dis Week (May 17, 2003, Orlando) 2003: Abst T1329.
50. Furst, D.E., Schiff, M.H., Fleischmann, R.M. et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30(12): 2563.
51. Meunier, P.J., Roux, C., Seeman, E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. New Engl J Med 2004, 350(5): 459.
52. Sun, W.J. et al. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res 2003, 9(14): 5221.
53. Advani, R., Fisher, G.A., Lum, B.L. et al. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res 2003, 9(14): 5187.
54. Ryan, D.P., O'Neil, B., Lima, C.R. et al. Phase I dose-escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 915.
55. Appelman, L.J., Ryan, D.P., Clark, J.W. et al. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 839.
56. O'Bryant, C.L. et al. A phase I study of the selective apoptotic antineoplastic drug (SAAND) CP-461 in patients (pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 942.
57. Piro, L.D. et al. KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 539.
58. Schacter, L.P., Bukowski, R.M., Carducci, M.A. et al. Safety profile of DHA-paclitaxel (TXP) in 8 phase II trials. Proc Am Soc Clin Oncol 2003, 22: Abst 856.
59. Scott, L.C., Soepenberg, O., Twelves, C. et al. A pharmacological comparison of phase I studies of diflomotecan (BN80915) administered orally and intravenously daily for 5 days every 3 weeks in patients with solid tumours. Proc Am Soc Clin Oncol 2003, 22: Abst 534.
60. Beer, T.M. et al. Phase I study and pharmacokinetic (PK) evaluation of DN-101, a new formulation of calcitriol. Proc Am Soc Clin Oncol 2003, 22: Abst 924.
61. O'Donnell, A., Faivre, S., Judson, I. et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 2003, 22: Abst 803.
62. Ibrahim, D., El-Rayes, B.F., Gadgeel, S.M., Lorusso, P., Philip, P.A. A phase I study of the protein kinase C modulator bryostatin-I and gemcitabine. Proc Am Soc Clin Oncol 2003, 22: Abst 930.
63. George, S. et al. Imatinib combined with chemotherapy in patients with solid tumors-myelotoxicity and fatigue are dose limiting in phase I trials. Proc Am Soc Clin Oncol 2003, 22: Abst 814.
64. Dittrich, C., Dumez, H., Calvert, H. et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003, 9(14): 5195.
65. Supko, J.G., Eder, J.P., Ryan, D.P. et al. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res 2003, 9(14): 5178.
66. Banerji, U., O'Donnell, A., Scurr, M. et al. A pharmacokinetically (PK) - pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG). Proc Am Soc Clin Oncol 2003, 22: Abst 797.
67. Solit, D.B., Anana, M., Valentin, G. et al. Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 795.
68. Hutson, T.E., Plavney, D., Mekhail, T. et al. A dose finding and pharmacokinetic study of the novel isoflavanoid phenoxodiol in patients with refractory malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 886.
69. Joshua, A.M. et al. Phase I dose-escalation study of phenoxodiol in patients with advanced cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 902.
70. Chow, S., Ramanathan, R.K., Kirkpatrick, L. et al. A phase I trial of thioredoxin inhibitor, PX-12, given as a 3-hour infusion in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 964.
71. Heymach, J. et al. Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin. Proc Am Soc Clin Oncol 2003, 22: Abst 979.
72. Hayes, T.G., Varadhachary, G.R., Smith, D., Hintz, D., Varadhachary, A., Falchook, G. Phase I/II clinical trial of oral recombinant human lactoferrin in the treatment of chemotherapy resistant solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 947.
73. Twarsowski, P.W. et al. Phase I trial of SU5416 in combination with weekly paclitaxel in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 944.
74. Lara, P., Frankel, P., Gumerlock, P.H. et al. Intermittent dosing of the farnesyl transferase inhibitor R115777 in advanced malignant solid tumors: A Phase I California Cancer Consortium Trial. Proc Am Soc Clin Oncol 2003, 22: Abst 878.
75. Mross, K., Scheulen, M.E., Licht, T. et al. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: A phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anti-Cancer Drugs 2004, 15(1): 15.
76. Twelves, C. et al. Phase I and pharmacokinetic study of Yondelis™ (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003, 39(13): 1842.
77. Repp, R., van Ojik, H.H., Valerius, T. et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003, 89(12): 2234.
78. Tonkin, K., Herbert, H., Lathia, C. et al. A phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 965.
79. Bogdanova, N., Lissianskaya, A., Gorelov, A. et al. Paclitaxel vitamin E emulsion: Phase I/II study of weekly administration in patients with non-small cell lung (NSCLC), transitional Cell (TCC), ovarian or colorectal cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 988.
80. Kieran, M.W. et al. Phase I trial and pharmacokinetic study of intravenous SU5416 in pediatric central nervous system tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 986.
81. Reyno, L., Seymour, L., Tu, D. et al. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-21738001) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 2004, 22(2): 269.
82. Hawkins, M., Desai, N., Soon-Shiong, P. Rationale, preclinical support, and clinical proof-of-concept for formulating water-insoluble therapeutics as albumin-stabilized nanoparticles: Experience with paclitaxel. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17, 2003, Boston) 2003: Abst A3.
83. Miles, D., Ibrahim, N., Roche, H. et al. An international, randomized phase III clinical trial of STn-KLH (Theratope) therapeutic cancer vaccine in metastatic breast cancer patients. Breast Cancer Res Treat 2003, 82 (Suppl. 1): Abst 36.
84. Esteva, F.J., Rivera, E., Cristofanilli, M. et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 67.
85. von Minckwitz, G. et al. A multicenter phase II trial to evaluate gefitinib ("Iressa", ZD1839) (500 mg/day) in patients with metastatic breast cancer after previous chemotherapy treatment. Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 437.
86. Gray, R. et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc Am Soc Clin Oncol 2003, 22: Abst 825.
87. Pierga, J.-Y. et al. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 840.
88. Mani, S., McDaid, H., Goel, S. et al. Expanded evaluation of BMS-247550 (BMS) using a lhr infusion at the recommended phase II dose (RPTD). Proc Am Soc Clin Oncol 2003, 22: Abst 995.
89. Subongkot, S. et al. Potential interaction of imatinib mesylate with c-kit positive breast cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 931.
90. Armstrong, D.K., Blessing, J.A., Rader, J., Sorosky, J.I. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs 2003, 21(4): 453.
91. Kroening, H., Hochster, H., Grothey, A. et al. Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer: A phase I dose escalation study. Proc Am Soc Clin Oncol 2003, 22: Abst 1459.
92. Mita, A.C., Hammond, L.A., Garrison, M. et al. A phase I and pharmacokinetic (PK) study of the dolastatin 15 analog ILX651 administered IV weekly × 3 weeks every 4 weeks in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 906.
93. Spriggs, D.R., Dupont, J., Pezzulli, S. et al. KOS-862 (Epothilone D): Phase I dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 894.
94. Salazar, R. et al. A phase 1/2A open-label study of EKB-569 in combination with CPT-II/5-FU/LV (FOLFIRI) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 888.
95. Benson, A.B. et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2003, 22: Abst 975.
96. Siu, L., Awada, A., Takimoto, C.H. et al. Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 828.
97. Hussain, M., Vaishampayan, U., Heilbrun, L.K. et al. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest New Drugs 2003, 21(4): 465.
98. Davis, N.B., Taber, D.A., Ansari, R.H. et al. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004, 22(1): 115.
99. Vaishampayan, U.N., Heilbrun, L., Jain, V., Zwiebel, J., Flaherty, L., Hussain, M. Modest disease stabilization (DS) with fenretinide in advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003, 22: Abst 960.
100. Lorus Therapeutics announces interim clinical results of GTI-2040 in combination chemotherapy for the treatment of renal cell cancer. Lorus Therapeutics Press Release 2004.
101. Hidalgo, M., Atkins, M.B., Stadler, W.M. et al. A randomized double-blind phase 2 study of intravenous (IV) CCI-779 administered weekly to patients with advanced renal cell carcinoma (RCC): Prognostic factor analysis. Proc Am Soc Clin Oncol 2003, 22: Abst 804.
102. Dutcher, J.P., Hudes, G., Motzer, R. et al. Preliminary report of a phase I study of intravenous (IV) CCI-779 given in combination with interferon-α (IFN) to patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003, 22: Abst 854.
103. Thodtmann, R., Sauter, T., Weinknecht, S. et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003, 21(3): 353.
104. Garland, L.L., Gitlitz, B., Ebbinghaus, S. et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. Proc Am Soc Clin Oncol 2003, 22: Abst 911.
105. Vermorken, J.B., Stupp, R., Nguyen, L., Pinel, M.-C., Delord, J.-P. Phase I study of IV vinflunine given on a weekly schedule in previously untreated patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 887.
106. Cappuzzo, F. et al. Mitogen-activated protein kinase (MAPK) and Akt as predictive factors for response to ZD 1839 therapy in non-small cell lung cancer (NSCLC) patients. Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 805.
107. De Marinis, F. et al. Impact of third line ZD 1839 therapy on patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme). Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 798.
108. Gatzemeier, U. et al. Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib. Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 52.
109. Tada, H. et al. Adjuvant therapy with gefitinib ("Iressa", ZD1839) following complete resection in Japanese patients with non-small-cell lung cancer: Safety report of the first 38 patients recruited. Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 811.
110. Winegarden, J.D. et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer (Ireland) 2003, 39(2): 191.
111. Chan, A.T.C., Hsu, M.M., Goh, B.C. et al. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003, 22: Abst 2000.
112. Hussain, M. et al. Occurrence of ascites secondary to STI571 in ovarian cancer patients. Proc Am Soc Clin Oncol 2003, 22: Abst 880.
113. Rader, J.S., Clarke-Pearson, D., Moore, M. et al. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol 2003, 91(2): 318.
114. Morgan, J.A. et al. Preliminary report of a phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 788.
115. Briasoulis, E., Pavlidis, N., Terret, C. et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 2003, 39(16): 2334.
116. Millward, M. et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003, 22: Abst 912.
117. Willett, C.G., Boucher, Y., di Tomaso, E. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2): 145.
118. Börjesson, P.K.E. et al. Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003, 9(10): 3961S.
119. Rischin, D., Peters, L., Smith, J. et al. Preliminary results of TROG 98.02 - a randomized phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2003, 22: Abst 1992.
120. Soulieres, D., Senzer, N.N., Vokes, E.E., Hidalgo, M., Agarwala, S.S., Siu, L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22(1): 77.
121. Haddad, R.I., Shapiro, G.I., Weinstein, L. et al. A phase II study of E7070 in patients with metastatic, recurrent, or refractory head and neck squamous cell carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation. Proc Am Soc Clin Oncol 2003, 22: Abst 800.
122. Remick, S.C. et al. P-5340: A phase I pharmacokinetic study of STI-571 in patients (pts) with advanced malignancies and varying degrees of renal dysfunction. Proc Am Soc Clin Oncol 2003, 22: Abst 503.
123. Rich, J.N., Reardon, D.A., Peery, T. et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22(1): 133.
124. van den Bent, M.J., Grisold, W., Frappaz, D. et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003, 14(12): 1732.
125. Hau, P., Bogdahn, U., Grauer, O. et al. Intratumoral treatment of high-grade glioma with a TGF-β-2 antisense oligonucleotide (API2009): Safety and first efficacy data of a clinical phase I/II dose escalation study. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abst 5361.
126. Giles, F.J. et al. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003, 27(12): 1077.
127. Zimmerman, T.M., Harlin, H., Odenike, T. et al. Dose-ranging pharmacodynamic study of RII5777 in patients with refractory hematologic malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 853.
128. Elter, T., Borchmann, P., Reiser, M. et al. Development of a new, four-weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL. Proc Am Soc Clin Oncol 2003, 22: Abst 2331.
129. Hochhaus, A., Fischer, T., Bruemmendorf, T. et al. Combination therapy of chronic myelogenous leukemia (CML) with imatinib and pegylated interferonalpha2a. Proc Am Soc Clin Oncol 2003, 22: Abst 2287.
130. Orlowski, R.Z., Voorhees, P.M., Garcia, R. et al. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 801.
131. O'Connor, O.A. et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas. Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abst 1009.
132. Wooldridge, J., Link, B.K., Weisdorf, D.J. et al. Phase I study of oligodeoxynucleotide CpG 7909 in patients with previously treated non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2003, 22: Abst 843.
133. Ragupathi, G., Livingston, P.O., Hood, C. et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003, 9(14): 5214.
134. Jagannath, S., Richardson, P., Barlogie, B. et al. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): Assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol 2003, 22: Abst 2341.
135. Dendreon's Provenge extends survival in advanced prostate cancer by over eight months in patients with Gleason scores of seven and less. Dendreon Press Release 2004
136. Casali, P.G., Casanova, M., Dileo, P. et al. Activity of ecteinascidin-743 (ET,trabectedin) 3-hour infusion in adult and childhood small round cell sarcomas. Proc Am Soc Clin Oncol 2003, 22: Abst 962.
137. Yang, H.H., Vescio, R.A., Adams, J., Schenkein, D., Berenson, J.R. A phase I/II study of combination treatment with bortezomib and melphalan (Vc+M) in patients with relapsed or refractory multiple myeloma (MM). Proc Am Soc Clin Oncol 2003, 22: Abst 2340.
138. De Deyn, P.P., Jeste, D., Aubey, P. et al. A ripiprazole for psychosis of Alzheimer's disease. 11th Int Congr Int Psychogeriatr Assoc (Aug 17, 2003, Chicago) 2003: Abst PA-010.
139. Arroyo, S., Anhut, H., Kugler, A.R. et al. Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004, 45(1): 20.
140. Scharf, M., Seiden, D., Erman, M., Rosenberg, R., McCall, V., Wessel, T. Eszopiclone rapidly induced sleep and provided sleep maintenance in elderly patients with chronic insomnia. 11th Int Congr Int Psychogeriatr Assoc (Aug 17, 2003, Chicago) 2003: Abst S092-004.
141. Ivanenko, A., Crabtree, V.M., Taumann, T., Gozal, D. Melatonin in children and adolescents with insomnia: A retrospective study. Clin Pediatr 2003, 42(1): 51.
142. Smits, M.G., Van Stel, H.F., Van der Heijden, K., Meijer, A.M., Coenen, A.M., Kerkhof, G.A. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: A randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003, 42(11): 1286.
143. Baskett, J.J., Broad, J.B., Wood, P.C. et al. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing 2003, 32(2): 164.
144. Smith, T., Nett, R. Frovatriptan is well tolerated during repeated use for prophylaxis of menstrually associated migraine. Headache 2003, 43(5): Abst S165.
145. Tepper, S., Freitag, F. Prophylactic use of frovatriptan for menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period. Headache 2003, 43(5): Abst S162.
146. Black, J. et al. A 12-month, open-label, multicenter extension trial of
147. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004, 62(2): 330.
148. Pettigrew, L.C., Kasner, S.E., Kwiatkowski, T. et al. Safety and tolerability of ONO-2506 in acute ischemic stroke. Stroke 2004, 35(1): Abst P208.
149. Pettigrew, L.C., Kasner, S.E., Gorman, M., Atkinson, R.P., Dietrich, D., Ishibashi, H. ONO-2506 suppresses S-100β in ischemic stroke patients. Stroke 2004, 35(1): Abst P184.
150. Rosenberg, G., Angel, I., Kozak, A., Schneider, D. Evaluation of safety and changes in the NIH stroke scale, Rankin, and Barthel scores following DP-b99 administration to acute stroke patients. Stroke 2004, 35(1): Abst P443.
151. Teal, P. The effect of intravenous repinotan on acute ischemic stroke outcomes (BRAINS). Stroke 2004, 35(1): Abst 29.
152. Saltarelli, M.D., Weaver, J.J., Hsu, C., Bednar, M.M. Randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of CP-101,606 (traxoprodil), an NR2B-selective N-methyl D-aspartate receptor antagonist, in subjects with acute ischemic stroke. Stroke 2004, 35(1): Abst 35.
153. Bushara, K.O., Goldstein, S.R., Grimes, G.J. Jr., Burstein, A.H., Hallett, M. Pilot trial of 1-octanol in essential tremor. Neurology 2004, 62(1): 122.
154. Wohlreich, M.M., Brannan, S.K., Mallinckrodt, C.H. et al. Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst P38.
155. Natarajan, S., Ahsan, N. Melatonin improves sleep quality (SQ) in end stage renal disease (ESRD) patients - A prospective, randomized, double blind, placebo-controlled, cross-over study. J Am Soc Nephrol 2003, 14: Abst SU-PO811.
156. Kostic, D., McQuade, R.D., Saha, A.R. et al. Pooled analysis of the safety and tolerability profile of aripiprazole in schizophrenia. 11th Int Congr Int Psychogeriatr Assoc (Aug 17, 2003, Chicago) 2003: Abst PD-034.
157. Hillmen, P., Hall, C., Marsh, J.C.W. et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med 2004, 350(6): 552.
158. Rosano, G.M., Aversa, A., Vitale, C. et al. Effect of chronic therapy with phosphodiesterase 5 inhibitor tadalafil on endothelial function. Circulation 2003, 108 (17, Suppl. 4): Abst 3329.
159. Spalding, J.R., Kowalski, J., Lee, J., Glaser, D.A. Effect of pharmacologic treatment on dermatologic-specific quality of life (QOL): A comparison of botulinum toxin type-A (BT-A) for primary focal hyperhidrosis (HH) to medical treatment for other dermatological diseases. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P197.
160. Mathias, S.D., Kahler, K.H., Kianifard, F., Abrams, K.H. The quality of life benefits of pimecrolimus cream 1% in the long-term management of mild to severe pediatric atopic dermatitis. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P236.
161. Siegfried, E.C., Korman, N., Abrams, K. Long-term management with pimecrolimus cream 1% for atopic dermatitis reduces flare frequency and corticosteroid use. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P9.
162. Kempers, S., Jarrat, M., Pariser, D., Carter, E. Pimecrolimus cream 1% demonstrates better local tolerability than tacrolimus ointment 0.03% in pediatric patients with atopic dermatitis. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P12.
163. Kaufmann, R., Folster-Holst, R., Hoeger, P., Wahn, U. Pimecrolimus cream 1% significantly improves atopic dermatitis in infants aged 3-23 months within 3 days of treatment. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P242.
164. Papp, K., Kapp, A., Ruer-Mulard, M., Davidson, M.J. Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P245.
165. Barbeau, M., Deutsch, G., Castilloux, A.-M., Kleinstiver, P. Assessment of quality of life and resource utilization in patients with atopic dermatitis: The Rainbow study. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P234.
166. Grad, O., Niren, N., Sung, J., Law, A. Impact of atopic dermatitis treatment on quality of life: Results from Findings in Atopic Children with Eczema (FACE) study. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P248.
167. Jones, T., Rich, P., Smith, S.R., Torok, H.M. A triple combination agent in the treatment of melasma. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P540.
168. Torok, H., Wills, I., Brody, N., Wieder, J. An 8 month efficacy and safety evaluation of a triple combination agent in the treatment of melasma. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P539.
169. van de Kerkhof, P., Vaishnaw, A., Kragballe, K., Ortonne, J.-P. Alefacept is efficacious in a broad spectrum of patients with psoriasis. J Eur Acad Dermatol Venereol 2003, 17 (Suppl. 1): Abst PP1-42.
170. Leonardi, C., Goffe, B., Sobell, J., Caro, I. The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P613.
171. Papp, K., Mease, P., Garovoy, M., Zhang, D. Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P609.
172. Gordon, K., Pariser, D., Langley, R., Caro, I. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P4.
173. Menter, A., Hamilton, T., Caro, I., Chen-Rundle, A. Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P608.
174. Stone, S., Papp, K., Caro, I., Bresnahan, B. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P610.
175. Gottlieb, A., Gordon, K., Caro, I., Leonardi, C. Long-term efalizumab therapy safely maintains Psoriasis Area and Severity Index improvement: Preliminary results from an open-label trial. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P611.
176. Sitruk-Ware, R., Small, M., Kumar, N., Tsong, Y.Y., Sundaram, K., Jackanicz, T. Nestorone®: Clinical applications for contraception and HRT. Steroids 2003, 68(10-13): 907.
177. Wiltshire, H., Paya, C., Pescovitz, M.D. et al. Pharmacodynamics of safety and efficacy for ganciclovir after its oral administration and from its pro-drug, valganciclovir, in solid organ transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 1396.
178. Hill, J.A., Dorent, R., Valantine, H., Parameshwar, J., Cretin, N. Reduced incidence of CMV infection in heart transplant patients treated with everolimus. Am J Transplant 2003, 3 (Suppl. 5): Abst 67.
179. Hare, J., Starling, R.C., Renlund, D., Mancini, D., Mayer, H.W., Schmidli, H. Therapeutic drug monitoring of everolimus may be beneficial in de novo heart transplantation. Am J Transplant 2003, 3 (Suppl. 5): Abst 63.
180. Mancini, D., Vigano, M., Pulpon, L.A. et al. 24-month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 1553.
181. Pescovitz, M.D., Paya, C., Humar, A. et al. Valganciclovir for prevention of CMV disease: 12 month follow up of a randomized trial of 364 D+/R- transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 575.
182. Oppenheimer, F., Oyen, O., Viljoen, H., Vitko, S., Falcone, A., Cremer, M. 36-month results of an International study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 1201.
183. Whelchel, J.D., Eris, J., Campbell, S. et al. Therapeutic Drug Monitoring (TDM) for everolimus: Modeling of efficacy based on two kidney transplantation trials with implemented TDM. Am J Transplant 2003, 3 (Suppl. 5): Abst 1163.
184. Garnick, J., Haririan, A., Sillix, D. et al. Cytomegalovirus (CMV) prophylaxis with valganciclovir (VAL) based on donor/recipient (D/R) serostatus in African-American (AA) renal allograft recipients (RAR). Am J Transplant 2003, 3 (Suppl. 5): Abst 1381.
185. Ciancio, G., Burke, G., Zvi, L. et al. Valganciclovir prophylaxis for cytomegalovirus disease in kidney and simultaneous pancreas-kidney transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 1379.
186. Sundberg, A.K., Rohr, M.S., Adams, P.L., Stratta, R.J. Safety and efficacy of valganciclovir for CMV prophylaxis in high-risk kidney and pancreas transplant recipients. Am J Transplant 2003, 3 (Suppl. 5): Abst 574.
187. Scheffler, M.R., Teo, S., Stirling, D., Thomas, S., Khetani, V. Multiple dosing of dexmethylphenidate HCL (d-MPH) does not result in accumulation or interconversion to l-methylphenidate HCL in male and female children. Clin Pharmacol Ther 2003, 73(2): Abst P11-27.
188. Nosek, L., Heinemann, L., Kaiser, M., Amolds, S., Heise, T. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003, 52 (Suppl. 1): Abst 551-P.
189. Boyle, J. et al. Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): S365.
190. Haig, G.M., Giordani, B., Randinitis, E.J., Mitchell, D.Y. Evaluation of the pharmacodynamic and pharmacokinetic interaction between pagoclone and ethanol. Clin Pharmacol Ther 2003, 73(2): Abst PDII-A.
191. Syed, T.A., Wong, W.H., Ahmad, S.A., Aly, R. Phase II, clinical evaluation of 2% polyphenon E (green tea extract) in a hydrophilic gel to assess improvement in damaged and premature aged facial skin. A placebo-controlled, double-blind study. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P98.
192. Dawe, R.S., Ibbotson, S.H., Sanderson, J.B., Thomson, E.M., Ferguson, J. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol 2003, 149(6): 1232.